Synergistic effects of ezetimibe with low dose simvastatin in lowering Lipid parameters- a pilot study
Abstract
Objective: To find out see the effect on lipid parameters by using a combination of the two drugs.
Materials and methods This was a randomized, double-blind, placebo-controlled trial conducted in conformance with good clinicalpractices and consisted of 2 phases: A total of 39 patients were enrolled in the study. Patients were randomly assigned to receive either simvastatin alone or a combination of simvastatin plus ezetimibe. It was conducted at Fauji Foundation Hospital Rawalpindi from July 2008 to September 2008.
Results Mean baseline total cholesterol ranged from 5.29 to 8.87 mmol/ L. The results indicated that the total cholesterol levels reduced significantly (p <0.05) from the baseline when patients were given 10 mg Simvastatin. Upon reduction of dose of simvastatin to 5 mg and addition of ezetimibe 10 mg, the levels of total cholesterol reduced even further (p<0.05). Similar results were seen with triglyceride levels (p<0.05). There was no statistically significant difference in LDL-C levels from the baseline with the use of simvastatin 10 mg alone. However co-administration of ezetimibe (10mg) to simvastatin (5mg) caused a statistically significant reduction in LDL-C levels from the baseline. There was no effect on HDL–C, ALT, blood glucose levels. The pilot study confirmed the effectiveness of ezetimbe in lowering total cholesterol and LDL–C levels in combination with reduced doses of simvastatin.
Conclusions Ezetimibe should be considered an effective lipid-lowering agent that can be used in conjunction with simvastatin at the beginning of therapy, or included in the treatment of patients who do not achieve their total and low-density lipoprotein cholesterol goal with statins alone.Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2016 Sami Saeed, Dawar Majeed Bhatti, Amjad Nasim, Amna Khan

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Readers may “Share-copy and redistribute the material in any medium or format” and “Adapt-remix, transform, and build upon the material”. The readers must give appropriate credit to the source of the material and indicate if changes were made to the material. Readers may not use the material for commercial purpose. The readers may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
